JSF Financial LLC Has $654,000 Position in Johnson & Johnson (NYSE:JNJ)

JSF Financial LLC lowered its stake in Johnson & Johnson (NYSE:JNJFree Report) by 25.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 4,200 shares of the company’s stock after selling 1,453 shares during the quarter. JSF Financial LLC’s holdings in Johnson & Johnson were worth $654,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of JNJ. Hibernia Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $27,000. FNY Investment Advisers LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $37,000. Tower View Wealth Management LLC boosted its holdings in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 165 shares during the last quarter. Creative Capital Management Investments LLC boosted its holdings in Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after acquiring an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth about $48,000. Institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Trading Up 0.2 %

Shares of JNJ opened at $156.76 on Monday. The business’s 50-day moving average price is $158.20 and its 200-day moving average price is $158.73. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The stock has a market cap of $377.37 billion, a PE ratio of 11.35, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. During the same period in the prior year, the business posted $2.35 earnings per share. The company’s revenue was down 9.7% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.04%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on JNJ. Raymond James boosted their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $167.00 to $180.00 in a report on Friday, December 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, January 24th. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $176.14.

View Our Latest Research Report on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.